Clincosm LogoSign in Get a demo

HATCH: Helping Adults Perform Transvaginal Exams Via Coaching at Home

Sponsor
Turtle Health, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05282524
Collaborator
(none)
90
Enrollment
1
Location
2
Arms
11.6
Anticipated Duration (Months)
7.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To train ultrasound technologists (equivalently called sonographers) in remote ultrasound guidance.

To capture imaging of the gynecologic organs visible on home ultrasound and pertinent to clinical care, specifically the ovaries and uterus.

To train the independent readers, both obstetricians & gynecologists (OB/GYNs) and reproductive endocrinologists (REIs), who will evaluate home ultrasound images over time in subsequent clinical trials.

Condition or Disease Intervention/Treatment Phase
  • Device: Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
HATCH (Helping Adults Perform Transvaginal Exams Via Coaching at Home) Study: Protocol for Training Ultrasound Technologists to Conduct At-home, Remote Transvaginal Ultrasounds
Actual Study Start Date :
Mar 23, 2022
Anticipated Primary Completion Date :
Mar 10, 2023
Anticipated Study Completion Date :
Mar 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Simulated patient

Women recruited from a general population subject to inclusion/exclusion criteria, who will participate at a minimum four times in the study

Device: Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)
Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.
Experimental: Naive patient

Women recruited from a general population subject to inclusion/exclusion criteria, who will participate only once in the study

Device: Transvaginal ultrasound performed by a woman herself (with remote healthcare professional supervision)
Imaging performed by woman on herself with remote healthcare professional (HCP) supervision. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.

Outcome Measures

Primary Outcome Measures

  1. Video quality of remote self-performed ultrasound exam [1 visit (up to 1 hour)]

    Determination of whether each organ view is 'diagnostic quality' or 'not diagnostic quality' based on American Institute of Ultrasound in Medicine (AIUM) criteria/guidelines

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Women aged 18 and over who have not gone through menopause (defined as no menstruation for at least 12 months, not explained by other causes)

  • Women with body mass index (BMI) up to 40

  • Women who speak English, assessed through screening questions

  • Women with at least a high school degree or equivalent (e.g., General Educational Development (GED) or similar)

  • Women located in Massachusetts

  • Women who are able to safely receive delivery of the ultrasound scanner

  • Women between cycle days 3 and 10 at the time of testing as a mitigation against potential inadvertent early fetal exposure; or intrauterine device (IUD) users who do not have a menses

  • Women who have all three primary gynecological organs: left ovary, right ovary, and uterus

Exclusion Criteria:

  • Women with BMI over 40

  • Women who do not speak English natively or fluently

  • Women who have recently given birth, and have had fewer than 3 postpartum menstrual cycles

  • Women who have recently had a stillbirth or abortion more than 20 weeks (subject to the 3 postpartum menstrual cycles above). Miscarriages or abortions less than 20 weeks are subject to two wait cycles

  • Women who are currently pregnant or may be pregnant

  • Women who have had a hysterectomy or oophorectomy

  • Women who have changed birth control within the current menstrual cycle. (One 'washout' cycle is required)

  • Women with cancer of any pelvic organ

  • Women who are not able to schedule an exam while meeting the requirements above prior to the end of the trial. For example, women who change birth control within the last cycle of the trial (and would require a 'washout cycle' that would delay trial close) or who are unable to schedule within the last few weeks of the trial after reasonable scheduling efforts have been made may be excluded.

  • Women with disabilities are excluded only if their disability precludes their ability to manipulate an ultrasound and follow technologist instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Virtual metasite Boston Massachusetts United States 02110

Sponsors and Collaborators

  • Turtle Health, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Turtle Health, Inc.
ClinicalTrials.gov Identifier:
NCT05282524
Other Study ID Numbers:
  • 011
First Posted:
Mar 16, 2022
Last Update Posted:
Apr 29, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Apr 29, 2022